Triglyceride to HDL-C ratio is associated with plasma D-dimer levels in different types of pancreatitis

Xiaoqing Jia¹, Xiaoting Zhang², Dalong Sun², Na Yang², Rong Li² & Zheng Luo²*

This study aims to evaluate levels of D-dimer and serum lipid in different types of pancreatitis, and the relationship between D-dimer and dyslipidemia, especially triglyceride to HDL-C ratio (TG/HDL-C) in different types of pancreatitis. We analyzed the D-dimer and dyslipidemia levels in acute pancreatitis (AP), recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP). A single-centered retrospective study was conducted on 1013 patients diagnosed with AP, RAP or CP. Only patients hospitalized within 24 h of onset were included, and 204 patients were enrolled in pancreatitis groups. 68 normal persons without pancreatitis, malignant diseases, pregnancy, or organ failure, who had health check-ups, were enrolled in the control group. Blood samples were taken within 24 h of admission. The relevant information on epidemiology and etiology was collected. D-dimer and serum lipid levels in different types of pancreatitis were analyzed. Furthermore, the area under the receiver-operating characteristic curve (AUC) was used to estimate the validity of the predictor and to define optimal cut-off points for prediction. We found that D-dimer and TG/HDL-C ratio could distinguish mild AP (MAP) and non-MAP in AP and RAP patients. The D-dimer level was related to TG/HDL-C ratio and severity of pancreatitis, with the coefficient correlation of 0.379 and 0.427(p < 0.05), respectively. TG/HDL-C was related to D-dimer in different types of pancreatitis. Logistic regression analysis was conducted in the parameters at admission like alcohol abuse, dyslipidemia and coagulation disturbance in distinguishing AP and RAP groups from the control group, and the parameter like diabetes in RAP and CP groups significantly increased compared with that of the control group. The value of D-dimer level and TG/HDL-C ratio in predicting the severity of AP and RAP was confirmed but there was no significant difference between CP group and the control group. The D-dimer level was related to dyslipidemia and TG/HDL-C ratio.

Abbreviations
AP  Acute pancreatitis
RAP  Recurrent acute pancreatitis
CP  Chronic pancreatitis
BISAP  Bedside index for severity in acute pancreatitis
AUC  An area under the curve
TG  triglyceride
Cho  Cholesterol
LDL-C  Low-density lipoprotein cholesterol
HDL-C  High-density lipoprotein cholesterol
NEFA  Non-esterified fatty acids

Acute pancreatitis (AP) occurs due to the autodigestion of the pancreatic enzymes. It is an acute inflammatory process characterized by severe pain localized in the upper abdomen which may be radiating towards the back and can trigger a systemic inflammatory response⁴. Recurrent acute pancreatitis (RAP) is a clinical condition characterized by repeated episodes of acute pancreatitis, which is diagnosed retrospectively by clinical definition

¹Department of Gastroenterology and Hepatology, Qilu Hospital of Shandong University, 107 West Wenhua Road, Jinan 250012, Shandong, China. ²Department of Geriatric Medicine, Qilu Hospital, Shandong University, 107 West Wenhua Road, Jinan 250012, Shandong, China. ²email: lizzyrichie@163.com
after at least the second episode of AP\(^1\). RAP is an intermediary stage in the pathogenesis of chronic pancreatitis (CP), and a subset of RAP patients during their natural course transition to CP\(^1\). CP involves progressive inflammatory and fibrotic changes of the exocrine pancreas, which could result in permanent structural damage and lead to impairment of both endocrine and exocrine functions\(^2\). It is known that the socioeconomic burden of pancreatitis is significant given the presence of symptoms and the costs to the health system\(^3\). The severe form, accounting for 20–30% of acute pancreatitis patients is a life-threatening disease with high nosocomial mortality\(^4\). Therefore, identifying risk factors for RAP in patients with AP as early as possible may improve prevention and early treatment, thereby improving prognosis.

Pancreatitis induces venous thrombosis\(^5\)–\(^8\). The pathogenesis of pancreatitis is release and activation of numerous proinflammatory cytokines leading to hypercoagulation and microvascular thrombosis, which may result in multi-organ dysfunction, splenic thrombosis and venous thromboembolism\(^9\)–\(^13\). Thrombosis is a vascular complication of pancreatitis and a major cause of morbidity and mortality. Chronic pancreatitis accompanied by isolated thrombosis of the splenic vein is caused by perivenous inflammation of RAP\(^15\).

D-dimer is the cleavage product of cross-linked fibrin that is formed by activation of the coagulation system, which signals hyperfibrinolysis in response to clot activation and fibrin formation\(^16\). D-dimer assays are commonly used in clinical practice to diagnose deep vein thrombosis or pulmonary embolism\(^17\). Recently, D-dimer levels are elevated in a variety of conditions, including coronary artery disease, infection and atrial fibrillation\(^18\)–\(^20\). D-dimer is also found to be an early predictor of severity of acute pancreatitis\(^21\). However, the correlation between D-dimer levels and different types of pancreatitis is relatively unexplored.

Dyslipidemia include a low level of high-density lipoprotein cholesterol (HDL-C) and increased level of triglyceride (TG). The triglyceride to HDL-C ratio (TG/HDL-C) summarizes the combined effect of each level and can be used as a better predictor for insulin resistance, cardio-metabolic risk, and cardiovascular disease\(^21\)–\(^23\).

To our knowledge, few studies have evaluated TG/HDL-C ratios in different types of pancreatitis, and the relationship between TG/HDL-C and D-dimer has not been investigated.

In the present study, the plasma levels of D-dimer in patients with AP, RAP and CP were measured. Subsequently, correlations between D-dimer levels and different types of pancreatitis were assessed.

**Results**

**Patient and control characteristics.** Of 1013 patients with pancreatitis, 204 patients were enrolled and their serum D-dimer levels were all measured within 24 h of hospital admission. Baseline demographic and clinical characteristics were analyzed toward 95 patients with AP, 47 patients with RAP and 62 patients with CP (Fig. 1). Besides, 68 patients without pancreatitis, malignant diseases, pregnancy, or organ failure, who had regular physical check-ups, were enrolled in the control group. Of the 95 patients with AP, 40.00% were female and 60.00% were male, the median age was 50. In the RAP group, 27.66% were female and 72.34% were male, the median age was 45. Of the patients with CP, females were 20.97%, and males were 79.03%, the median age was 52.5. In the control group, 33.82% were female and 66.18% were male, with a median age of 51 (Table 1).

In AP patients, 35.79% had a smoking history, 41.05% had a history of drinking alcohol, 32.63% had hypertension, 9.47% had a history of cardiovascular disease (CVD), 13.68% had type 2 diabetes, 20.00% had allergy history, 5.26% had family chronic diseases, 23.16% had dyslipidemia and 70.53% had coagulation disorder. In RAP patients, 44.68% had a smoking history, 38.30% had a history of drinking alcohol, 14.89% had hypertension, 17.02% had a history of cardiovascular disease (CVD), 25.33% had type 2 diabetes, 17.02% had allergy history, 8.51% had family chronic diseases, 19.15% had dyslipidemia and 57.45% had coagulation disorder. In CP patients, 61.29% had a smoking history, 67.74% had a history of drinking alcohol, 30.65% had hypertension, 8.06% had a history of cardiovascular disease (CVD), 29.03% had type 2 diabetes, 9.68% had allergy history, 8.06% had family chronic diseases, 1.61% had dyslipidemia and 25.81% had coagulation disorder. Also, common etiologies, including biliary dysfunction, hypertriglyceridemia, alcoholism and idiopathic pancreatitis in different types of pancreatitis were shown in Table 1.

**Gender, age, smoking status, alcohol drinking status, allergic history, presence of CVD, hypertension, type 2 diabetes, dyslipidemia, and coagulation disorder of these patients had been undergone logistic regression analysis. AP patients with coagulation disorder had an odds ratio (OR) of 13.88 (95% CI 6.22–30.98; P = 0.00) compared with patients in control group (Table 1). RAP patients with coagulation disorder had an OR of 12.53 (95% CI 5.51–28.49; P = 0.00) compared with patients in control group. AP patients with dyslipidemia had an OR of 8.40 (95% CI 4.11–17.15; P = 0.00) compared with patients in control group. RAP patients with dyslipidemia had an OR of 10.24 (95% CI 4.74–22.11; P = 0.00) compared with patients in control group. CP patients with dyslipidemia had an OR of 2.46 (95% CI 1.16–5.19; P = 0.02). CP patients with coagulation disorder had no significant difference compared with control group. AP patients with alcohol abuse had an OR of 6.74 (95% CI 2.18–20.85; P = 0.00) compared with patients in control group. RAP patients with alcohol abuse had an OR of 7.41 (95% CI 1.8–30.55; P = 0.01) compared with patients in control group. CP patients with alcohol abuse had an OR of 18.89 (95% CI 3.84–93; P = 0.00) compared with patients in control group. RAP patients with type 2 diabetes had an OR of 7.73 (95% CI 2.08–28.69; P = 0.00) compared with patients in control group. CP patients with type 2 diabetes had an OR of 6.71 (95% CI 1.73–26.06; P = 0.01) compared with patients in control group, besides AP patients with type 2 diabetes had no significant difference compared with control group. RAP patients with heart disease had an OR of 10.15 (95% CI 1.91–53.82; P = 0.01) compared with patients in control group. There was no significant association in age, gender, smoking, hypertension, family chronic disease and allergic history between patients with different types of pancreatitis and the control group.
D-dimer, dyslipidemia and TG/HDL-C ratios in different types of pancreatitis. In different types of pancreatitis, D-dimer levels in AP patients and RAP patients were significantly higher than those in control group (p < 0.05), and there was no significant difference in D-dimer levels between CP group and control group (Table 2, Fig. 2). AP and RAP patients were subdivided into MAP and non-MAP groups (MSAP and SAP groups). For the prediction of severity of AP, the area under curve (AUC) of non-MAP group for serum D-dimer levels was 0.851 (p < 0.05), the cut-off value was 1.13 mg/dL. For the prediction of RAP severity, the AUC of non-MAP group for serum D-dimer levels was 0.80 (p < 0.05), the cut-off value was 2.14 mg/dL (Table 3, Fig. 4).

In this study, the severities of pancreatitis were recognized according to 2012 Atlanta classification, and measured by BISAP score\(^2\), the BISAP scores of AP patients were significantly higher than those of RAP group (p < 0.05). The correlation coefficient between the BISAP score and D-dimer level was 0.427 (p < 0.05) (Table 2, Fig. 2). Our studies showed that in different types of pancreatitis, the dyslipidemia was significantly different between the AP, RAP group and the control group. Therefore, dyslipidemia in each group was analyzed. Levels of HDL-C in different types of pancreatitis were significantly lower than those in control group but had no significant difference between each pancreatic group. Levels of TG and non-esterified fatty acid (NEFA) were significantly higher in AP and RAP groups than those in control group (p < 0.05) but were not significantly different between AP and RAP groups. TG/HDL-C ratios in different types of pancreatitis were significantly higher than those in control group (Table 2, Fig. 3). The relationship between D-dimer level and dyslipidemia occurrence was analyzed, and the correlation coefficient between them was 0.33 (p < 0.05) (Table 2). For the prediction of RAP severity, AUC of non-MAP group for TG/HDL-C ratio was 0.84 (p < 0.05), the cut-off value was 3.51 (Table 3, Fig. 4). For the prediction of the relationship between TG/HDL-C and D-dimer level in pancreatitis, the patients were divided into D-dimer elevated group and normal D-dimer group, the AUC of D-dimer elevated group for TG/HDL-C ratio was 0.69 (p < 0.05), the cut-off value was 2.56 (p < 0.05), in RAP the AUC was 0.73, and the cut-off value was 2.10, but there is no significant relationship between D-dimer and TG/HDL-C ratio in CP group (Table 3, Fig. 4).
Table 1. Patients’ characteristics and predictors by univariate analysis in different types of pancreatitis. AP acute pancreatitis, RAP recurrent acute pancreatitis, CP chronic pancreatitis. *p < 0.05; **p < 0.01.

| Variable               | AP   | RAP   | CP    | Control |
|------------------------|------|-------|-------|---------|
| **Gender**             |      |       |       |         |
| Female (N%)            | 40.00% | 27.66% | 20.97% | 33.82%  |
| Male (N%)              | 60.00% | 72.34% | 79.03% | 66.18%  |
| OR (95% CI)            | 0.77 (0.40–1.47) | 1.35 (0.67–2.72) | 1.93 (0.87–4.25) |       |
| **Age**                |      |       |       |         |
| Median age             | 50 (18–91) | 45 (22–94) | 52.5 (30–78) | 51 (18–79) |
| OR (95% CI)            | 1.00 (0.97–1.03) | 1.00 (0.98–1.02) | 0.97 (0.93–1.01) |       |
| **Smoking**            |      |       |       |         |
| No (N%)                | 64.21% | 55.32% | 38.71% | 77.94%  |
| Yes (N%)               | 35.79% | 44.68% | 61.29% | 22.06%  |
| OR                     | 0.98 (0.24–4.10) | 2.71 (0.39–18.85) | 1.07 (0.18–6.47) |       |
| **Alcoholic abuse**    |      |       |       |         |
| No (N%)                | 58.95% | 61.70% | 32.26% | 86.76%  |
| Yes (N%)               | 41.05% | 38.30% | 67.74% | 13.24%  |
| OR (95% CI)            | 3.98 (1.48–24.15)* | 9.12 (1.31–63.6)* | 26.65 (4.39–161.67)** |       |
| **Hypertension**       |      |       |       |         |
| No (N%)                | 67.37% | 85.11% | 69.35% | 80.88%  |
| Yes (N%)               | 32.63% | 14.89% | 30.65% | 19.12%  |
| OR (95% CI)            | 1.70 (0.50–5.72) | 0.74 (0.10–5.15) | 1.35 (0.32–5.74) |       |
| **Heart disease**      |      |       |       |         |
| No (N%)                | 90.53% | 82.98% | 91.94% | 95.59%  |
| Yes (N%)               | 9.47%  | 17.02% | 8.06%  | 4.41%   |
| OR (95% CI)            | 4.88 (0.61–39.26) | 16.64 (0.58–475.29) | 10.64 (1–113.62) |       |
| **Diabetes**           |      |       |       |         |
| No (N%)                | 86.32% | 74.47% | 78.97% | 92.65%  |
| Yes (N%)               | 13.68% | 25.53% | 21.03% | 7.35%   |
| OR (95% CI)            | 0.81 (0.07–2.40) | 2.67 (0.29–24.65) | 7.36 (1.28–42.23)* |       |
| **Allergic history**   |      |       |       |         |
| No (N%)                | 80.00% | 82.98% | 90.32% | 89.71%  |
| Yes (N%)               | 20.00% | 17.02% | 9.68%  | 10.29%  |
| OR (95% CI)            | 2.95 (0.71–12.23) | 2.22 (0.35–13.89) | 0.90 (0.15–5.25) |       |
| **Family chronic disease** |       |       |       |         |
| No (N%)                | 94.74% | 91.49% | 91.94% | 98.53%  |
| Yes (N%)               | 5.26%  | 8.51%  | 8.06%  | 1.47%   |
| OR (95% CI)            | 6.27 (0.05–794.39) | 1.88E + 08 (0–) | 4.1E + 07 (0–) |       |
| **Dyslipidemia**       |      |       |       |         |
| No (N%)                | 76.84% | 80.85% | 98.39% | 75.00%  |
| Yes (N%)               | 23.16% | 19.15% | 1.61%  | 25.00%  |
| OR (95% CI)            | 8.40 (4.11–17.15)** | 10.24 (4.74–22.11)** | 2.09 (0.63–6.91) |       |
| **Coagulation disorder** |       |       |       |         |
| No (N%)                | 29.47% | 42.55% | 74.19% | 85.29%  |
| Yes (N%)               | 70.53% | 57.45% | 25.81% | 14.71%  |
| OR (95% CI)            | 13.88 (6.22–30.98)** | 12.53 (5.51–28.49)** | 3.43 (0.63–6.91) |       |
| **Etiology**           |      |       |       |         |
| Alcoholic              | 15.79% | 14.89% | 32.26% |       |
| Biliary                | 64.21% | 34.04% | 53.23% |       |
| Hypertriglyceridemia   | 5.26%  | 17.02% | 0.00%  |       |
| Idiopathic             | 14.74% | 10.64% | 14.52% |       |
| **Severity**           |      |       |       |         |
| MAP                    | 86.32% | 93.62% |       |       |
| MSAP                   | 8.42%  | 4.26%  |       |       |
| SAP                    | 5.26%  | 2.13%  |       |       |
Discussion

Characters of patients with different types of pancreatitis. RAP refers to a clinical entity characterized by episodes of acute pancreatitis which occurs on more than one occasion. An established chronic disease may be found either on the occasion of the first episode of pancreatitis or during the follow-up. RAP was the strongest predicting factor for a subsequent diagnosis of CP.\(^{26,27}\) The etiology and epidemiology of AP, RAP and CP were studied in this research. The results showed that coagulation disorder is related to AP and RAP group, with OR of 13.88 and 12.53 (\(P < 0.05\)) respectively compared with patients in control group, and D-dimer levels in AP and RAP groups were significantly higher than those of the control group. However, coagulation disorder and D-dimer levels had no significant difference between CP group and control group. The D-dimer level is also related to the severity of pancreatitis. This result was confirmed in other studies, which showed that D-dimer was an early predictor of the severity of AP.\(^{28-30}\) The possible mechanism may be two-sided: the abnormal activation of pancreatic enzymes results in inflammation and injury to the pancreas at the onset of AP, which then induces thrombosis and further aggravates the injury.\(^{31,32}\) The systemic inflammatory response syndrome and multiple organ dysfunction syndromes, which occur in patients with AP, are common risk factors for the development of VTE.\(^{33}\) The propagation of the acute inflammatory response can lead to chronic inflammation if there is no appropriate resolution.\(^{34,35}\) On a molecular level, pancreatic stellate cells (PaSCs) have been found to play an important role in models of CP. In CP, PaSCs participate in pathogenesis after transforming into an activated or "myofibroblastic" state.\(^{36}\) In this myofibroblastic state, PaSCs produce collagen and other extracellular matrix proteins that lead to fibrosis. PaSCs also secrete cytokines which further promote the inflammatory process.\(^{37}\) However, the D-dimer levels of CP patients were not very different from those of the control group; the reason

| Dyslipidemia | AP (mean ± SD) | RAP (mean ± SD) | CP (mean ± SD) | Control (mean ± SD) | DDi correlation coefficient |
|-------------|---------------|----------------|----------------|---------------------|---------------------------|
| Cho (mmol/L) | 4.49 ± 2.10   | 4.84 ± 1.62    | 4.29 ± 2.37    | 4.35 ± 0.81         | −0.12                     |
| TG (mmol/L)  | 2.23 ± 2.36** | 2.58 ± 2.20**  | 1.62 ± 1.31    | 1.21 ± 0.49         | 0.141*                    |
| HDL-C (mmol/L) | 0.9 ± 0.42** | 0.97 ± 0.42**  | 1.04 ± 0.32**  | 1.25 ± 0.25         | −0.35                     |
| LDL-C (mmol/L) | 2.59 ± 0.96  | 2.69 ± 1.06    | 2.65 ± 2.19    | 2.59 ± 0.63         | −0.14                     |
| NEFA (umol/dl) | 61.07 ± 40.2** | 50.97 ± 24.12* | 48.37 ± 28.33  | 39.09 ± 24.94       | 0.146*                    |
| TG/HDL-C     | 3.08 ± 3.09** | 4.74 ± 10.86*  | 1.73 ± 1.76*   | 1.05 ± 0.73         | 0.379**                    |
| BISAP score  | 1.29 ± 0.11*  | 0.96 ± 0.1     |                |                     | 0.427**                    |
| DDi (mg/dl)  | 1.46 ± 2.47** | 1.32 ± 2.25**  | 0.46 ± 0.80    | 0.24 ± 0.26         |                           |

Table 2. Dyslipidemia and severity in types of pancreatitis. AP acute pancreatitis, RAP recurrent acute pancreatitis, CP chronic pancreatitis, TG triglyceride, Cho cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, NEFA non-esterified fatty acids, BISAP bedside index of severity in acute pancreatitis. *\(p < 0.05\); **\(p < 0.01\).
may be that the severity of inflammation in CP patients was less than that of AP and RAP groups. Besides, the fibrotic changes of the pancreas may not induce acute inflammation and coagulation disturbance. A study about splanchnic venous thrombosis (SVT) suggested that local inflammation plays a major role in SVT causation. Thrombophilia caused by coagulation disturbance is seen in one-third of patients with AP but does not seem to increase the risk of SVT.

Our study shows that dyslipidemia is related to different types of AP, RAP and CP, with OR of 8.40, 10.24 and 2.46 (p < 0.05) respectively, and dyslipidemia is also related to D-Dimer level. In previous studies, dyslipidemia, especially hypertriglyceridemia, is related to AP and RAP, the pathophysiology could be the metabolism of excessive TGs by pancreatic lipase to non-esterified fatty acids (NEFA) leading to pancreatic cell injury and ischemia. A 3558-patient study comparing high triglyceride-AP (HTG-AP) versus non-HTG-AP reported a statistically significant higher incidence of pancreatic necrosis, infected pancreatic necrosis, organ failure, and persistent organ failure. Recent studies demonstrate a trend towards severity in patients with HTG-AP when compared with non-HTG pancreatitis patients; the patients with higher TG levels appear to have more severe hospital courses with a higher incidence of complications (35–69%) and organ failure (20–35%)..

Researches have shown that patients with diabetes, obesity, or metabolic syndrome due to insulin resistance tend to have low HDL-C because of lower lipoprotein lipase activity and triglyceride enrichment, but the mechanism is still unknown. The TG/HDL-C ratio was found to be associated with insulin resistance in overweight and obese children. Our research shows that in AP and RAP patients, TG and NEFA levels of which were significantly higher than those of CP and control group, HDL-C levels of AP, RAP and CP groups were lower than those of the control group (p < 0.05), which may be related to insulin resistance in all types of pancreatitis. The TG/HDL-C ratio is also a potential useful marker to identify the severity of RAP patients in clinical practice, with positive predictive value of 0.84 at 3.51 cut-off point. TG/HDL-C ratio was related to insulin resistance, which may occur after acute pancreatitis. In our research, TG/HDL-C ratio is found to be a predictor of severity in RAP patients but not in first attack of AP. The mechanism may be that hypertriglyceridemia (HTG) is a well-established cause of RAP, and TG/HDL-C ratio is predictable in RAP. The relationship between insulin resistance and RAP should be further investigated.

We also found that D-dimer level was related to TG/HDL-C ratio (r = 0.379, p < 0.05). A previous study has shown that both TG and acute pancreatitis could cause an elevation in d-dimer level, in which TG plays a more important role. In type 2 diabetic children and adolescents, D-dimer level was significantly correlated with TG (p < 0.05).

The pathogenesis may be PSCs, which are activated directly by alcohol and its metabolites, and also by cytokines and growth factors released during alcohol-induced pancreatic necro-inflammation. Activated PSCs are the key cells responsible for fibrosis of alcoholic chronic pancreatitis. Our research shows that alcoholism is related to AP, RAP and CP groups, with OR of 6.74, 7.41 and 18.89 (p < 0.05) respectively.

### Table 3. ROC cure and cut-off value of D-dimer and dyslipidemia in different types of pancreatitis. AP acute pancreatitis, RAP recurrent acute pancreatitis, CP chronic pancreatitis, TG triglyceride, Cho cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, NEFA non-esterified fatty acids, AUC area under the receiver-operating characteristic curve. The severity of pancreatitis was subdivided into MAP and non-MAP groups.

|                  | AP         | RAP        | CP         |
|------------------|------------|------------|------------|
|                  | AUC | Cut-off value | p  | AUC | Cut-off value | p  | AUC | Cut-off value | p  |
| Dyslipidemia vs severity of pancreatitis | Cho  | 0.17 | 0.00 | 0.21 | 2.22 | 0.05 |
|                  | TG   | 0.50 | 0.97 | 0.63 | 2.09 | 0.39 |
|                  | HDL-C| 0.25 | 0.00 | 0.34 | 1.42 | 0.29 |
|                  | LDL-C| 0.14 | 0.28 | 10.50 | 0.14 |
|                  | NEFA | 0.46 | 237.00 | 0.65 | 0.28 | 10.50 | 0.14 |
|                  | TG/HDL-C| 0.61 | 2.17 | 0.22 | 0.84 | 5.51 | 0.02 |
| Dyslipidemia vs Ddi | Cho  | 0.36 | 0.42 | 0.02 | 0.50 | 5.98 | 0.98 |
|                  | TG   | 0.61 | 1.37 | 0.08 | 0.70 | 2.17 | 0.00 |
|                  | HDL-C| 0.26 | 0.36 | 1.49 | 0.03 | 0.23 | 0.00 |
|                  | LDL-C| 0.36 | 3.86 | 0.02 | 0.48 | 3.52 | 0.74 |
|                  | NEFA | 0.45 | 40.50 | 0.46 | 0.55 | 42.50 | 0.44 |
|                  | TG/HDL-C| 0.69 | 2.56 | 0.00 | 0.73 | 2.10 | 0.00 |
Our research shows that diabetes is related to RAP and CP. The pathogenesis is that RAP and CP, which are pancreatic inflammation with irreversible parenchymal damage and functional changes, is complicated by progressive nutrient maldigestion, glucose intolerance, diabetes mellitus, and metabolic derangements. Destruction of islet cells by pancreatic inflammation can lead to the development of "brittle" disease with wide swings in blood sugar which are difficult to control. Besides, patients may have pre-existing risk factors for type 2 diabetes, such as insulin resistance, obesity, or dietary habits that further complicate the optimal regulation of glucose metabolism. In our study, diabetes was related to RAP and CP groups, with OR of 7.73 and 6.71 (p < 0.05), but had no relationship to the AP group.

In our study, heart disease is related to RAP, with OR of 10.15 (p < 0.05). So far, research on association between heart and pancreas disease has been paid little attention and its role in pathogenesis is not fully elucidated. The pathogenesis could be pancreatic enzymes and their inhibitors that profoundly affected blood coagulation and appear to influence the course of pancreatic inflammation. Researches have shown that in patients with chronic heart failure, the splanchnic circulation is decreased, especially in highly vascularized pancreas, which may cause pancreatitis.

There are no significant differences in other factors like smoking, hypertension, etc. between pancreatitis and the control group. Although we drew similar conclusions from recent studies, our research had significant advantages. We distinguished different types of pancreatitis between AP, RAP and CP groups. RAP is a syndrome that...

**Figure 3.** Dyslipidemia in different types of pancreatitis. (a) Dyslipidemia in different types of pancreatitis; (b) Free fatty acid in different types of pancreatitis; (c) TG/HDL-C ratio in different types of pancreatitis. *p < 0.05; **p < 0.01.
of multiple distinct acute inflammatory responses originating within the pancreas in individuals with genetic, environmental, traumatic, morphologic, metabolic, biologic, and/or other risk factors who experienced 2 or more episodes of documented AP, and RAP may lead to chronic pancreatitis. Approximately 9% to 31% of patients with AP develop RAP. To our knowledge, no similar investigations about a comparison between AP, RAP and CP groups have been investigated in China. In our research, the epidemiology and etiological factors of RAP are similar to those of first attack AP; also D-Dimer levels and dyslipidemia were similar in the RAP and the AP groups. However, the D-Dimer level, dyslipidemia and severity of pancreatitis in CP group were similar to those of the control group.

The present research has several limitations. Firstly, it was conducted in a single center with a relatively small sample, which may create bias. Secondly, we did not take into account some inflammation factors, such as PCT,
or 6.00 mmol/L, high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL or 0.8 mmol/L, low-density lipoprotein cholesterol (LDL-C) ≥ 160 mg/dL or 3.37 mmol/L, or triglyceride (TG) ≥ 200 mg/dL or 1.7 mmol/L. These simple and feasible markers and index could be used in clinical practice to improve early management of AP and RAP, which suggests that the early intervention of coagulation disturbance and dyslipidemia could be substantial. The relationship between D-dimer and dyslipidemia need further investigation.

Material and methods
In this observational study, the data of all patients were retrospectively collected from Shandong University Qilu hospital from January 1, 2017 to December 31, 2020. The ethics committee of Qilu Hospital of Shandong University reviewed and approved this study (No.KYLL-202008-096). All the data are anonymous, and the requirement for informed consent was therefore waived. The informed consent waiver statement was approved by the ethics committee of Qilu Hospital of Shandong University. The approval was supported in Supplementary Material.

Study population. A review of all medical registries with International Disease Classification-10 diagnoses related to AP and CP from January 2017 to December 2020 in Shandong University Qilu hospital was performed; RAP patients were selected from AP patients on the basis of RAP definition.

According to the Atlanta classification and definition of acute pancreatitis, AP was defined as the presence of two or more of the following: (a) abdominal pain compatible with AP, (b) serum amylase and/or lipase values ≥ 3 times upper limits of normal, (c) imaging findings of APREF. RAP was defined as 2 or more well-documented separate attacks of AP with complete resolution for 3 or more months between attacks according to current definition of RAPREF. CP patients were selected from patients with CP diagnosis and with typical features of epigastric pain, steatorrhea, weight loss, or recurrent acute pancreatitis, and CT or MRI results which were considered consistent with chronic pancreatitis according to the American Pancreatic Association Practice GuidelinesREF. Normal persons without pancreatitis, malignant diseases, pregnancy, or organ failure, who had health check-ups were enrolled in the control group.

The exclusion criteria were as follows and the flow chart was shown in Fig. 1:

(a) Participants who failed to meet the definition of AP, RAP or CP were excluded in each group.
(b) In AP and RAP groups, variables obtained from laboratory exams over the first 24 h of the onset of symptoms were excluded.
(c) Participants younger than 18 or pregnant participants were excluded.
(d) Participants with pre-existing chronic diseases like malignant tumor, heart diseases, liver diseases and renal diseases which may influence the variables were excluded. Participants with traumatic pancreatitis were also excluded in present study.
(e) Participants with incomplete information were excluded.

The severities of AP and RAP patients were well recognized according to the latest 2012 revision of the Atlanta classification. Mild AP (MAP) patients were not associated with organ failure (OF) and local or systemic complications. Moderately severe AP (MSAP) was characterized by the presence of transient OF (less than 48 h) or local or systemic complications. Severe AP (SAP) was defined as persistent OF for more than 48 h. The diagnosis of OF was based on the modified Marshall scoring system, and a score of 2 or more was considered to be the presence of OF of the respiratory, cardiovascular, or renal systemsREF. BISAP score was used to assess the severity of pancreatitis. Individual components of the BISAP scoring system were shown in Table 4REF.

Data collection. Age, gender, medical history, and admission number of each patient were collected as baseline demographic data. Moreover, we recorded values of vital signs of all patients on admission and important laboratory parameters. D-dimers were measured in hospital with standard operation procedure; the upper limit of normal value for D-dimer is 0.55 mg/L. Cholesterol (Cho), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglyceride (TG) were detected in Department of Laboratory of Qilu Hospital. Prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen, and thrombin time were also collected. Values of patients who had 2 or more attacks were counted as the average values of every episode. Patients were considered to have dyslipidemia if total cholesterol (Cho) > 240 mg/dL or 6.00 mmol/L, high-density lipoprotein cholesterol (HDL-C) < 40 mg/dL or 0.8 mmol/L, low-density lipoprotein cholesterol (LDL-C) ≥ 160 mg/dL or 3.37 mmol/L, or triglyceride (TG) ≥ 200 mg/dL or 1.7 mmol/L. Coagulation disorder was recorded if an extension of the PT (> 13.8 s) or an extension of the APTT (> 42 s) or D-dimer > 0.55 mg/L occurred. All methods were performed in accordance with the relevant guidelines and regulations.
BISAP scoring system

| Blood urea Nitrogen (BUN) > 25 mg/dL |
| Impaired mental status (Glasgow Coma Scale Score < 15) |
| Systemic Inflammatory Response Syndrome (SIRS): |
| SIRS is defined as presence of two or more of the following |
| (1) Temperature of < 36 or > 38 °C |
| (2) Respiratory rate > 20 breaths/min or P a CO2 < 32 mm Hg |
| (3) Pulse > 90 beats/min |
| (4) WBC < 4000 or > 12,000 cells/mm 3 or > 10% immature bands |
| Age > 60 years |
| Pleural effusion detected on imaging |

Table 4. BISAP scoring system. BISAP bedside index of severity in acute pancreatitis, WBC white blood count. One point is assigned for each variable within 24 h of presentation and added for a composite score of 0–5.

Statistic analysis. All statistical analyses were performed using two-tailed test and SPSS version 17.0 and GraphPad Prism v8.0 for Windows (SPSS, Chicago, IL). Data was presented as mean with standard deviation (SD). Comparisons between variables were performed by the one-way ANOVA analysis. For associations between 2 variables, Pearson’s chi-square test or Spearman rank correlation test was applied, as appropriate. The area under the receiver-operating characteristic (ROC) curve (AUC) was used to assess the predictive accuracy of severity of pancreatitis and to determine the optimum cut-off points with optimal sensitivity and specificity. The AUC was calculated using 95% confidence interval (CI). Bivariate logistic regression analysis was adjusted for potential confounding variables, and the odds ratios (OR) and 95% confidence intervals (CI) were calculated. P value less than 0.05 was considered statistically significant.

Data availability
All data generated or analysed during this study are included in this published article and its Supplementary Information files.

Received: 31 December 2021; Accepted: 25 July 2022
Published online: 28 July 2022

References
1. Henzen, C., Röck, M., Schnieper, C. & Heer, K. [Heparin and insulin in the treatment of acute hypertriglyceridemia-induced pancreatitis]. Schweiz. med. Wochenschr. 129, 1242–1248 (1999).
2. Testoni, P. A. Acute recurrent pancreatitis: Etiopathogenesis, diagnosis and treatment. World J. Gastroenterol. 20, 16891–16901 (2014).
3. Machicado, J. D. & Yadav, D. Epidemiology of recurrent acute and chronic pancreatitis: Similarities and differences. Dig. Dis. Sci. 62, 1683–1691 (2017).
4. Lew, D., Afghani, E. & Pandol, S. Chronic pancreatitis: Current status and challenges for prevention and treatment. Dig. Dis. Sci. 62, 1702–1712 (2017).
5. Kumar, S. et al. Risk factors associated with pediatric acute recurrent and chronic pancreatitis: Lessons from INSPIRE. JAMA Pediatr. 170, 562–569 (2016).
6. Leppäniemi, A. et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J. Emerg. Surg. 14, 27–27 (2019).
7. Berzigotti, A., García-Criado, A., Darnell, A. & García-Pagán, J. C. Imaging in clinical decision-making for portal vein thrombosis. Nat. Rev. Gastroenterol. Hepatol. 11, 308–316 (2014).
8. Toqué, L. et al. Predictive factors of splanchic vein thrombosis in acute pancreatitis: A 6-year single-center experience. J. Dig. Dis. 16, 734–740 (2015).
9. Maeda, K. et al. Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas 32, 87–92 (2006).
10. Feistritzer, C. & Wiedermann, C. J. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin. Biol. Ther. 7, 855–870 (2007).
11. Hagiwara, S. et al. Antithrombin III prevents cerulein-induced acute pancreatitis in rats. Pancreas 38, 746–751 (2009).
12. Franco-Avilés, L., Hernández-Rocha, F. I. & Mercado, U. Malvido-Torres CG [Segmental portal hypertension with splenic vein thrombosis caused by pancreatitis]. Rev. Med. Inst. Mexicano Seguro Soc. 55, 788–790 (2017).
13. Li, H., Yang, Z. & Tian, F. Clinical characteristics and risk factors for sinistral portal hypertension associated with moderate and severe acute pancreatitis: A seven-year single-center retrospective study. Med. Sci. Monit. 25, 5969–5976 (2019).
14. Xu, W., Qi, X., Chen, J., Su, C. & Guo, X. Prevalence of splanchnic vein thrombosis in pancreatitis: A systematic review and meta-analysis of observational studies. Gastroenterol. Res. Pract. 2015, 245460–245460 (2015).
15. Weber, S. M. & Rikkers, L. F. Splenic vein thrombosis and gastrointestinal bleeding in chronic pancreatitis. World J. Surg. 27, 1271–1274 (2003).
16. Olson, J. D. D-dimer: An overview of hemostasis and fibrinolysis, assays, and clinical applications. Adv. Clin. Chem. 69, 1–46 (2015).
17. Linkins, L. A. & Takach, L. S. Review of D-dimer testing: Good, Bad, and Ugly. Int. J. Lab. Hematol. 39(Suppl 1), 98–103 (2017).
18. Hijazi, Z., Oldgren, J., Siegbahn, A. & Wallentin, L. Application of biomarkers for risk stratification in patients with atrial fibrillation. Clin. Chem. 63, 152–164 (2017).
19. Watanabe, H. et al. Diagnostic test accuracy of D-dimer for acute aortic syndrome: systematic review and meta-analysis of 22 studies with 5000 subjects. Sci. Rep. 6, 26893 (2016).
20. Triant, V. A., Lee, H., Hadigan, C. & Grinspoon, S. K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. *J. Clin. Endocrinol. Metab.* 92, 2506–2512 (2007).

21. McLaughlin, T. *et al.* Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. *Am. J. Cardiol.* 96, 399–404 (2005).

22. Borrayo, G. *et al.* TG/HDL-C ratio as cardio-metabolic biomarker even in normal weight women. *Acta Endocrinol.* 14, 261–267 (2018).

23. Nur Zati Iwani, A. K. & Jalaludin, M. Y. TG: HDL-C ratio is a good marker to identify children affected by obesity with increased cardiometabolic risk and insulin resistance. *Int. J. Endocrinol.* 2019, 8586167 (2019).

24. Xia, W. *et al.* Elevated TG/HDL-C and non-HDL-C/HDL-C ratios predict mortality in peritoneal dialysis patients. *BMC Nephrol.* 21, 324 (2020).

25. Hagjer, S. & Kumar, N. Evaluation of the BISAP scoring system in prognostication of acute pancreatitis: A prospective observational study. *Int. Surg.* 54, 76–81 (2018).

26. Yadav, D., O’Connell, M. & Papachristou, G. I. Natural history following the first attack of acute pancreatitis. *Am. J. Gastroenterol.* 107, 1096–1103 (2012).

27. Lankisch, P. G. *et al.* Natural history of acute pancreatitis: A long-term population-based study. *Am. J. Gastroenterol.* 104, 2797–2805 (2009).

28. Wan, J. *et al.* Serum D-dimer levels at admission for prediction of outcomes in acute pancreatitis. *BMC Gastroenterol.* 19, 67 (2019).

29. Zhang, G. Q. *et al.* Plasma D-dimer level is an early predictor of severity of acute pancreatitis based on 2012 Atlanta classification. *Med. Sci. Monit.* 25, 9019–9027 (2019).

30. Gomercic, C. Assessment of D-dimers for the early prediction of complications in acute pancreatitis. *Pancreas* 45, 980–985 (2016).

31. Kakafika, A., Papadopoulos, V., Mimitidis, K. & Mikhalidis, D. P. Coagulation, platelets, and acute pancreatitis. *Pancreas* 34, 15–20 (2007).

32. Warzeka, Z. *et al.* Pretreatment with low doses of acenocoumarol inhibits the development of acute ischemia/reperfusion-induced pancreatitis. *J. Physiol. Pharmacol.* 66, 731–740 (2015).

33. Streiff, M. B. *et al.* Guidance for the treatment of deep vein thrombosis and pulmonary embolism. *J. Thromb. Thrombolysis* 41, 32–67 (2016).

34. Habtezion, A. Inflammation in acute and chronic pancreatitis. *Curr. Opin. Gastroenterol.* 31, 395–399 (2015).

35. Gukovsky, I., Li, N., Todoric, J., Gukovskaya, A. & Karin, M. Inflammation, autophagy, and obesity: Common features in the pathogenesis of pancreatitis and pancreatic cancer. *Gastroenterology* 144, 1199-1209.e1194 (2013).

36. Ömery, M. B., Lugea, A., Lowe, A. W. & Pandol, S. J. The pancreatic stellate cell: A star on the rise in pancreatic diseases. *J. Clin. Invest.* 117, 50–59 (2007).

37. Ahmed, S. U. *et al.* Role of thrombophilia in splanchnic venous thrombosis in acute pancreatitis. *Ann. Gastroenterol.* 31, 371–378 (2018).

38. Yan, P., Zhao, H.-X. & Chen, X. Suboptimal management of hypertriglyceridemia in the outpatient setting is associated with the recurrent pancreatitis: A retrospective cohort study. *Medicine* 99, e22887–e22887 (2020).

39. Scherer, J., Singh, V. P., Pitchumoni, C. S. & Yadav, D. Issues in hypertriglyceridemic pancreatitis: An update. *J. Clin. Gastroenterol.* 48, 195–203 (2014).

40. He, W. H. *et al.* Comparison of severity and clinical outcomes between hypertriglyceridemic pancreatitis and acute pancreatitis due to other causes. *Zhonghua yi xue za zhi* 96, 2569–2572 (2016).

41. Garg, R. & Rustagi, T. Management of hypertriglyceridemia induced acute pancreatitis. *Biomed. Res. Int.* 2018, 4723157 (2018).

42. Vergès, B. Lipid modification in type 2 diabetes: The role of LDL and HDL. *Fundam. Clin. Pharmacol.* 23, 681–685 (2009).

43. Amigó, N. *et al.* Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL-“Herniated” HDL, a common feature in diabetes. *Sci. Rep.* 6, 19249 (2016).

44. Holmes, M. V. *et al.* Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. *J. Am. Coll. Cardiol.* 71, 620–632 (2018).

45. Yoo, D. Y., Kang, Y. S., Kwon, E. B. & Yoo, E. G. The triglyceride-to-high density lipoprotein cholesterol ratio in overweight Korean children and adolescents. *Ann. Pediatr. Endocrinol. Metab.* 22, 158–163 (2017).

46. Ko, J., Skudder-Hill, L., Cho, J., Bharmai, S. H. & Petrov, M. S. The relationship between abdominal fat phenotypes and insulin resistance in non-obese individuals after acute pancreatitis. *Nutrients* 12, 2883 (2020).

47. Niebsz-Ciesla, A. B. & Karnafel, W. Insulin sensitivity in chronic pancreatitis and features of insulin resistance syndrome. *Pol. Arch. Med. Wewn.* 120, 255–263 (2010).

48. Kong, F. *et al.* D-Dimer change in human acute pancreatitis as determined by serumal triglyceride. *Pancreas* 40, 1103–1106 (2011).

49. Al-Asmar, M. A., Adly, A. A., El Hadidy, E. S. & Abdelwahab, M. A. D-dimer levels in type 1 and type 2 diabetic children and adolescents: Relation to microvascular complications and dyslipidemia “own data and review”. *Pediatr. Endocrinol. Rev.* 9, 657–668 (2012).

50. Lankisch, P. G., Apte, M. & Banks, P. A. Acute pancreatitis. *Lancet* 386, 85–96 (2015).

51. O’Farrell, A., Allwright, S., Doney, D., Bedford, D. & Conlon, K. Hospital admission for acute pancreatitis in the Irish population, 1997 2004: Could the increase be due to an increase in alcohol-related pancreatitis?. *J. Public Health* 29, 398–404 (2007).

52. Spanier, B. W., Dijkgraaf, M. G. & Bruno, M. J. Trends and forecasts of hospital admissions for acute and chronic pancreatitis in the Netherlands. *Eur. J. Gastroenterol. Hepatol.* 20, 653–658 (2008).

53. Apte, M. V., Pirolo, R. C. & Wilson, J. S. Mechanisms of alcoholic pancreatitis. *J. Gastroenterol. Hepatol.* 25, 1816–1826 (2010).

54. Riecke, M. R. *et al.* Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: Recommendations from PancreasFest 2012. *Pancreatology* 13, 336–342 (2013).

55. Cui, Y. & Andersen, D. K. Pancreatogenic diabetes: special considerations for management. *Pancreatology* 11, 279–294 (2011).

56. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 36(Suppl 1), S67-74 (2013).

57. Ewald, N. & Bretzel, R. G. Diabetes mellitus secondary to pancreatic diseases (Type 3c): Are we neglecting an important disease?. *Eur. J. Intern. Med.* 24, 203–206 (2013).

58. Nikolic, S. & chronic pancreatitis and the heart disease: Still terra incognita?. *World J. Gastroenterol.* 25, 6561–6570 (2019).

59. Nyman, L. R. *et al.* Real-time, multidimensional in vivo imaging used to investigate blood flow in mouse pancreatic islets. *J. Clin. Invest.* 118, 3790–3797 (2008).

60. Guda, N. M. *et al.* Recurrent acute pancreatitis: International state-of-the-science conference with recommendations. *Pancreas* 47, 653–666 (2018).

61. Gullo, L. *et al.* An update on recurrent acute pancreatitis: Data from five European countries. *Am. J. Gastroenterol.* 97, 1959–1962 (2002).

62. Gao, Y. J. *et al.* Analysis of the clinical features of recurrent acute pancreatitis in China. *J. Gastroenterol.* 41, 681–685 (2006).

63. Zhang, J., Niu, J. & Yang, J. Interleukin-6, interleukin-8 and interleukin-10 in estimating the severity of acute pancreatitis: An updated meta-analysis. *Hepatogastroenterology* 61, 215–220 (2014).

64. Harrison, D. A., D’Amico, G. & Singer, M. The Pancreatitis Outcome Prediction (POP) Score: A new prognostic index for patients with severe acute pancreatitis. *Crit. Care Med.* 35, 1703–1708 (2007).
65. Banks, P. A. et al. Classification of acute pancreatitis–2012: Revision of the Atlanta classification and definitions by international consensus. *Gut* **62**, 102–111 (2013).
66. Jagannath, S. & Garg, P. K. Recurrent acute pancreatitis: Current concepts in the diagnosis and management. *Current Treat. Opt. Gastroenterol.* **16**, 449–465 (2018).
67. Conwell, D. L. et al. American Pancreatic Association practice guidelines in chronic pancreatitis: Evidence-based report on diagnostic guidelines. *Pancreas* **43**, 1143–1162 (2014).
68. Singh, V. K. et al. A prospective evaluation of the bedside index for severity in acute pancreatitis score in assessing mortality and intermediate markers of severity in acute pancreatitis. *Am. J. Gastroenterol.* **104**, 966–971 (2009).

**Acknowledgements**

This work was supported by the Science Foundation of Qilu hospital Shandong University (no. 2015QLMS05).

**Author contributions**

Z.L., X.J. contributed to the conception of the study; Z.L., X.Z., R.L., N.Y. performed the data collection, statistical analysis and paper writing; X.J., D.S. helped perform the analysis with constructive discussions. All of the authors have read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-17421-7.

**Correspondence** and requests for materials should be addressed to Z.L.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022, corrected publication 2022